Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort.

Anne R SchlösserNeill BoeijinkJill OlydamTamar E C NijstenDirk-Jan Hijnen

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

In this real-world cohort, we confirmed that upadacitinib is an effective treatment in a subset of AD patients that have failed several previous systemic immunosuppressive and biologic treatments. Overall, AE were mostly well tolerated and not a reason to discontinue treatment for most patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
rheumatoid arthritis
patient reported outcomes
patient reported
drug induced